Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Leases (2021 - 2025)

Historic Current Leases for Avidity Biosciences (RNA) over the last 5 years, with Q3 2025 value amounting to $4.0 million.

  • Avidity Biosciences' Current Leases rose 428.5% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 428.5%. This contributed to the annual value of $3.8 million for FY2024, which is 563.34% up from last year.
  • As of Q3 2025, Avidity Biosciences' Current Leases stood at $4.0 million, which was up 428.5% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Current Leases registered a high of $4.0 million during Q3 2025, and its lowest value of $1.8 million during Q4 2021.
  • For the 5-year period, Avidity Biosciences' Current Leases averaged around $3.4 million, with its median value being $3.6 million (2023).
  • As far as peak fluctuations go, Avidity Biosciences' Current Leases surged by 7552.29% in 2022, and later soared by 270.53% in 2023.
  • Over the past 5 years, Avidity Biosciences' Current Leases (Quarter) stood at $1.8 million in 2021, then soared by 75.52% to $3.1 million in 2022, then increased by 17.2% to $3.6 million in 2023, then increased by 5.63% to $3.8 million in 2024, then grew by 3.2% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $3.9 million for Q2 2025, and $3.9 million during Q1 2025.